In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex (Q28343212)

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1319302

13 September 2022

R. J. Fass

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1319302

13 September 2022

language of work or name

English

0 references

publication date

1992

1 reference

PubMed

May 1992

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1319302

full work available at URL

13 September 2022

https://api.elsevier.com/content/article/PII:073288939290026P?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

https://api.elsevier.com/content/article/PII:073288939290026P?httpAccept=text/plain

6 December 2023

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Diagnostic Microbiology and Infectious Disease

6 December 2023

published in

0 references

volume

15

0 references

issue

4

0 references

page(s)

367-70

0 references

cites work

A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex

1

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Treatment of infections in patients with the acquired immunodeficiency syndrome

6 December 2023

2

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

In-vitro susceptibility of mycobacteria to ciprofloxacin.

6 December 2023

3

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Comparative in-vitro activity of five fluoroquinolones against mycobacteria

6 December 2023

4

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare

6 December 2023

5

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

6 December 2023

6

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome

6 December 2023

8

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

6 December 2023

9

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex

6 December 2023

10

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex

6 December 2023

11

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth

6 December 2023

12

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods

6 December 2023

13

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex

6 December 2023

14

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Antibacterial activity of coumermycin alone and in combination with other antibiotics

6 December 2023

16

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination

6 December 2023

17

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Evaluation of the BACTEC radiometric method for detection of 1% resistant populations of Mycobacterium tuberculosis.

6 December 2023

18

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Activity of ciprofloxacin against Mycobacteria in vitro: comparison of BACTEC and macrobroth dilution methods

6 December 2023

19

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Continuous high-grade mycobacterium avium-intracellulare bacteremia in patients with the acquired immune deficiency syndrome

6 December 2023

21

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome

6 December 2023

22

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome

6 December 2023

23

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Mycobacterium avium complex infection

6 December 2023

24

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria

6 December 2023

25

1 reference

https://api.crossref.org/works/10.1016/0732-8893(92)90026-P

6 December 2023

Identifiers

0 references